Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply.
Kelly CP, Green PH, Murray JA, Dimarino A, Colatrella A, Leffler DA, Alexander T, Arsenescu R, Leon F, Jiang JG, Arterburn LA, Paterson BM, Fedorak RN; Larazotide Acetate Celiac Disease Study Group. Kelly CP, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2013 Feb;37(4):496-7. doi: 10.1111/apt.12196. Aliment Pharmacol Ther. 2013. PMID: 23336684 No abstract available.
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
Kelly CP, Green PH, Murray JA, Dimarino A, Colatrella A, Leffler DA, Alexander T, Arsenescu R, Leon F, Jiang JG, Arterburn LA, Paterson BM, Fedorak RN; Larazotide Acetate Celiac Disease Study Group. Kelly CP, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2013 Jan;37(2):252-62. doi: 10.1111/apt.12147. Epub 2012 Nov 19. Aliment Pharmacol Ther. 2013. PMID: 23163616 Clinical Trial.
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Ma C, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2017 May;45(9):1232-1243. doi: 10.1111/apt.14016. Epub 2017 Mar 2. Aliment Pharmacol Ther. 2017. PMID: 28252210
Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, Millan M, Bailey R, Todoruk D, Cherry R, Teshima CW, Dieleman L, Fedorak RN. Waugh AW, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2010 Nov;32(9):1129-34. doi: 10.1111/j.1365-2036.2010.04446.x. Epub 2010 Aug 30. Aliment Pharmacol Ther. 2010. PMID: 20807218
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Feagan BG, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2015 Nov;42(10):1170-81. doi: 10.1111/apt.13398. Epub 2015 Sep 23. Aliment Pharmacol Ther. 2015. PMID: 26400458 Clinical Trial.
Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial.
van Rensburg C, Barkun AN, Racz I, Fedorak R, Bornman PC, Beglinger C, Balanzó J, Devière J, Kupcinskas L, Luehmann R, Doerfler H, Schäfer-Preuss S. van Rensburg C, et al. Aliment Pharmacol Ther. 2009 Mar 1;29(5):497-507. doi: 10.1111/j.1365-2036.2008.03904.x. Epub 2008 Nov 27. Aliment Pharmacol Ther. 2009. PMID: 19053987 Clinical Trial.
282 results